VIJAYA

** Shares of Metropolis Healthcare Ltd METP.NS rise 4.4% to 1,813.75 rupees

** Medical diagnostics firm reported a 15.5% rise in Q3 profit on higher sales of costlier tests after market hours on Tuesday; rev up 10%

** METP and larger rival Dr Lal PathLabs DLPA.NS rated "Hold", while analysts rate smaller rival Vijaya Diagnostic VIJA.NS "Buy" - LSEG

** Stock trims YTD losses to 12.8%, but trails DLPA's ~7% loss and VIJA's 11% climb this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Jan 13 (Reuters) - Vijaya Diagnostic Centre Ltd VIJA.NS:

• CFO NARASIMHA RAJU KA RESIGNS

Further company coverage: VIJA.NS

(([email protected];;))

Nov 7 (Reuters) - Vijaya Diagnostic Centre Ltd VIJA.NS:

• VIJAYA DIAGNOSTIC CENTRE SEPT-QUARTER CONSOL NET PROFIT 419.4 MILLION RUPEES

• VIJAYA DIAGNOSTIC CENTRE SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.83 BILLION RUPEES

Source text: ID:nBSE8HmytN

Further company coverage: VIJA.NS

(([email protected];))

** Shares of Krsna Diagnostics KRSN.NS up ~ 5% at 672.70 rupees

** Co on Tuesday reported 24% Y/Y surge in Q1 profit after tax, while rev rose 22%

** Stk down 6.3% YTD, biggest drag among diagnostic stocks

** Peers Vijaya Diagnostic VIJA.NS up 18% YTD, Thyrocare THYO.NS up ~ 21%, Metropolis Health METP.NS up 23%, Dr Lal Path DLPA.NS up 23%

** KRSN, Thyrocare "strong buy" rated on average; METP, DLPA "hold" rated, while VIJA "buy" rated - LSEG

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

June 26 (Reuters) - Medinova Diagnostic Services Ltd MAIN.BO:

• APPROVED SCHEME OF AMALGAMATION AMONGST CO, VIJAYA DIAGNOSTIC CENTRE

Further company coverage: MAIN.BO

(([email protected];))

** Shares of Dr. Lal PathLabs Ltd DLPA.NS up 6.6% at 2,379.60 rupees

** Medical diagnostics firm reports 49% jump in Q4 consolidated net profit, with revenue growing faster than expenses

** Stock was up 4% ahead of results

** Around 570,000 shares traded, 2x 30-day avg volume

** Analysts covering DLPA rate it "hold" on avg, same as Metropolis Healthcare METP.NS, vs "buy" for Vijaya Diagnostic Centre VIJA.NS - LSEG data

** DLPA reduces YTD losses to under 8% but trails METP's 4% rise and VIJA's 17% growth

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of Vijaya Diagnostic Centre VIJA.NS up as much as 6.9% to a record high of 724.25 rupees

** VIJA on Wednesday reported a near 22% rise in its consolidated net profit for the March-qtr to 334.5 mln rupees ($4 mln)

** Revenue from operations rose 28.3%

** More than 1 mln shares change hands by 11:47 a.m. IST, 6.9x their 30-day avg volume; busiest day yet since Feb. 7

** Average rating of six analysts covering the stock is "buy"; median PT is 680 rupees - LSEG data

** Including session's gain, stock is up 4.1% YTD, while rivals Metropolis Healthcare METP.NS is up 3.2%, and Dr. Lal Pathlabs DLPA.NS is down 12.4%

($1 = 83.4800 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

** Shares of Krsnaa Diagnostics KRSN.NS up as much as 4% to 598 rupees; last up 2.7%

** Pathology and radiology diagnostics services provider said it has signed an agreement with the government of Maharashtra state to provide MRI and CT scan services in district hospitals

** More than 151,000 shares traded as of 1:33 p.m. IST, 1.7x the 30-day moving avg

** Including session's move, stock is down 16.3% YTD, while peer Vijaya Diagnostic Centre VIJA.NS is up 0.4%

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Feb 5 (Reuters) - Vijaya Diagnostic Centre Ltd VIJA.NS:

• DEC-QUARTER CONSOL NET PROFIT 258.5 MILLION RUPEES VERSUS 163.6 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.33 BILLION RUPEES VERSUS 1.13 BILLION RUPEES

Further company coverage: VIJA.NS

(([email protected];))

** Shares of Vijaya Diagnostic Centre VIJA.NS rise as much as 7.41% to 675 rupees, a two-week high

** Diagnostics services provider's shares up about 8% in two sessions

** Rise after the company approved acquisition of P H Diagnostic Centre for 1.35 bln rupees, post market hours on Tuesday

** P H Diagnostic is Pune's largest business-to-consumer (B2C) integrated diagnostic chain, with a revenue of 416.3 mln rupees is fiscal 2023

** Stock up nearly 52% in 2023 so far, including session's gains, on course for best yearly performance since listing in 2021

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Vijaya Diagnostic Centre VIJA.NS rise nearly 3%

** Diagnostics firm on Tuesday said its board approved acquisition of P H Diagnostic Centre for 1.35 bln rupees ($16.23 mln)

** Stock set to gain for a third straight quarter, if trend holds; eyes biggest yearly rise since listing in 2021

** Share price above its 100-day simple moving average since June 14

($1 = 83.1909 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Aug 9 (Reuters) - Vijaya Diagnostic Centre Ltd VIJA.NS:

• INDIA'S VIJAYA DIAGNOSTIC CENTRE JUNE-QUARTER CONSOL NET PROFIT 262 MILLION RUPEES VERSUS PROFIT 174.5 MILLION RUPEES

• VIJAYA DIAGNOSTIC CENTRE JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.21 BILLION RUPEES VERSUS 1.04 BILLION RUPEES

Source text for Eikon: ID:nBSE6pcWtt

Further company coverage: VIJA.NS

(([email protected];;))

BENGALURU, May 11 (Reuters) - India's Dr. Lal PathLabs Ltd DLPA.NS on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from COVID-related testing outpaced growth in its core business.

The medical diagnostics firm, India's largest by revenue, posted a consolidated net profit of 567 million rupees ($6.93 million) in the three months to March 31, down from 613 million rupees a year earlier.

Earnings margin before interest, taxes, depreciation, and amortisation contracted to 23.6% from 24.9% a year ago.

Dr. Lal PathLabs is the first among its peers to report results and will set the tone for an intensely competitive industry that made a windfall during the pandemic but has since sharply slipped.

Shares of the company and its listed rivals Metropolis Healthcare METP.NS, Thyrocare Technologies THYO.NS and Vijaya Diagnostic Centre VIJA.NS have fallen between 45% and 68% from their all-time highs in 2021, as of their last close.

Analysts have since set their sights on companies' ability to widen their range of tests and geographic reach, noting that Dr. Lal PathLabs is best placed among its competitors to grow in the long term.

Over the period of more than a year, the company, which has a strong presence in northern and eastern India besides its New Delhi base, has sought to expand to smaller cities and other regions in the country through acquisitions.

Revenue grew a mere 1.1% to 4.91 billion rupees, with the non-COVID segment contributing to nearly 98% of the total.

Revenue from the COVID and allied segments was down to just 110 million rupees, from 660 million rupees a year before.

Shares of Dr. Lal PathLabs fell as much as 3.2% to 1,888.10 rupees after reporting results.

($1 = 81.7800 Indian rupees)

(Reporting by Nandan Mandayam in Bengaluru; Editing by Sonia Cheema)

(([email protected]; Mobile: +91 9591011727;))